A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

Expert Review of Hematology

Volumn 4, Issue 6, 2011, Pages 637-655

  Hasselbalch, Hans Carl ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

essential thrombocythemia; human leukocyte interferon; IFN 2; IFN a2b; pegylated IFN 2; Philadelphia negative chronic myeloproliferative neoplasms; polycythemia vera; post essential thrombocythemia myelofibrosis; post polycythemia vera myelofibrosis; primary myelofibrosis

Indexed keywords

ALPHA2 INTERFERON; HYDROXYUREA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RETICULIN;

ALOPECIA; ANEMIA; CHROMOSOME ABERRATION; COLONY FORMATION; CONFUSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GAIT DISORDER; GASTROINTESTINAL TOXICITY; GENOMIC INSTABILITY; GLOMERULONEPHRITIS; GRANULOCYTOPENIA; HEMOLYTIC ANEMIA; HUMAN; HYPOTHYROIDISM; IMMUNOCOMPETENT CELL; LEUKEMIA; LONG TERM CARE; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MYELOFIBROSIS; MYELOID METAPLASIA; NEURITIS; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; PREGNANCY; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THYROIDITIS; URTICARIA; WEIGHT REDUCTION;

ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; BONE MARROW; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC, ATYPICAL, BCR-ABL NEGATIVE; MYELOPROLIFERATIVE DISORDERS; NEOPLASM, RESIDUAL; POLYCYTHEMIA VERA; PREGNANCY; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 81255210738     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.63     Document Type: Review

References (213)

1. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16, 2825-2833 (1998). (Pubitemid 28363048)
2. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 26, 3603-3613 (2007). (Pubitemid 46844778)
3. Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol. 149, 3-13 (2010).
4. Weiner GJ. Rituximab: mechanism of action. Semin. Hematol. 47, 115-123 (2010).
5. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood Bcells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 54, 613-620 (2006). (Pubitemid 43228639)
6. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy - rare but there! Leuk. Lymphoma 50, 1083-1095 (2009).
7. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br. J. Haematol. 121, 913-918 (2003). (Pubitemid 36760311)
8. Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkins lymphoma. Bone Marrow Transplant 33, 921-923 (2004). (Pubitemid 38660125)
9. Dunleavy K, Hakim F, Kim HK et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106, 795-802 (2005). (Pubitemid 41076417)
10. Nitta E, Izutsu K, Sato T et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann. Oncol. 18, 364-369 (2007). (Pubitemid 46323107)
11. Cattaneo C, Spedini P, Casari S et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk. Lymphoma 47, 1013-1017 (2006). (Pubitemid 44102962)
12. Fukuno K, Tsurumi H, Ando N et al. Late-onset neutropenia in patients treated with rituximab for non-Hodgkins lymphoma. Int. J. Hematol. 84, 242-247 (2006). (Pubitemid 44619246)
13. Tesfa D, Gelius T, Sander Bet al. Late-onset neutropenia associated with rituximab therapy: Evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis. Med. Oncol. 25, 374-379 (2008).
14. Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am. J. Hematol. 84, 414-417 (2009).
15. Cairoli R, Grillo G, Tedeschi A, DAvanzo G, Marenco P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica 89, 361-363 (2004). (Pubitemid 38788425)
16. Hirayama Y, Kohda K, Konuma Y et al. Late-onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation. Intern. Med. 48, 57-60 (2009).
17. Marotte H, Paintaud G, Watier H, Miossec P. Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann. Rheum. Dis. 67, 893-894 (2008). (Pubitemid 351829397)
18. Rios-Fernandez R, Gutierrez-Salmeron MT, Callejas-Rubio JL, Fernandez-Pugnaire M, Ortego-Centeno N. Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases. Br. J. Dermatol. 157, 1271-1273 (2007). (Pubitemid 350119793)
19. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 60, 2156-2168 (2009).
20. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin. J. Am. Soc. Nephrol. 5, 1359-1362 (2010).
21. Tesfa D, Ajeganova S, Hagglund H et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with Blymphocyte depletion and infections. Arthritis Rheum. 63, 2209-2214 (2011).
22. Andersohn F, Konzen C, Garbe E. Systemic review: Agranulocytosis induced by nonchemotherpy drugs. Ann. Intern. Med. 146, 657-665 (2007). (Pubitemid 351650522)
23. Mosyagin I, Cascorbi I, Schaub R et al. Drug-induced agranulocytosis: impact of different fcgamma receptor polymorphisms? J. Clin. Psychopharmacol. 25, 435-440 (2005). (Pubitemid 41368365)
24. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am. J. Hematol. 84, 428-434 (2009).
25. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkins lymphoma. J. Clin. Oncol. 28, 279-284 (2010).
26. Li SC, Chen YC, Evens AM et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcgRIIIa 158(V/F) polymorphism. Am. J. Hematol. 85, 810-812 (2010).
27. Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N. Engl. J. Med. 348, 2691-2694; discussion 2691-2694 (2003).
28. Papadaki T, Stamatopoulos K, Stavroyianni N, Paterakis G, Phisphis M, Stefanoudaki- Sofianatou K. Evidence for T-large granular lymphocyte-mediated neutropenia in rituximab-treated lymphoma patients: Report of two cases. Leuk. Res. 26, 597-600 (2002). (Pubitemid 34462174)
29. + T cells from healthy elderly subjects suppress neutrophil development in vitro: implications of feltys and large granular lymphocyte syndromed. Arthritis Rheum. 43, 834-843 (2000).
30. Liu JH, Wei S, Lamy T et al. Chronic neutropenia mediated by fas ligand. Blood 95, 3219-3222 (2000). (Pubitemid 30321177)
31. Stamatopoulos K, Papadaki T, Pontikoglou C et al. Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 22, 1446-1449 (2008). (Pubitemid 352006092)
32. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 102, 1557-1558 (2003).
33. Rezvany MR, Jeddi-Tehrani M, Wigzell H, Osterborg A, Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood 101, 1063-1070 (2003). (Pubitemid 36139380)
34. Terrier B, Ittah M, Tourneur L et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica 92, e20-e3 (2007).
35. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J. Exp. Med. 201, 1771-1780 (2005). (Pubitemid 41002896)
36. Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin. Hematol. 43, 185-195 (2006).
37. Carlsson G, Andersson M, Putsep K et al. Kostmann syndrome or infantile genetic agranulocytosis, part one: celebrating 50 years of clinical and basic research on severe congenital neutropenia. Acta Paediatr. 95, 1526-1532 (2006). (Pubitemid 44863801)
38. Carlsson G, Andersson M, Putsep K et al. Kostmann syndrome or infantile genetic agranulocytosis, part two: understanding the underlying genetic defects in severe congenital neutropenia. Acta Paediatr. 96, 813-819 (2006).
39. Carlsson G, Aprikyan AG, Tehranchi R et al. Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome C, and excessive apoptosis of myeloid progenitor cells. Blood 103, 3355-3361 (2004). (Pubitemid 38525664)
40. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgRIIIa genotype to degree of Bcell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48, 455-459 (2003). (Pubitemid 36278014)
41. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99, 754-758 (2002). (Pubitemid 34525533)
42. Kato H, Yamamoto K, Matsuo K et al. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: Association with an incremental risk of infectious events. Ann. Oncol. 21, 1699-1705 (2010).
43. Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD 20 monoclonal antibody therapy in non-Hodgkins̀ lymphoma : safety and efficay of re-treatment. J. Clin. Oncol. 18, 3135-3143 (2000).
44. Van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction : Results of a prospective randomized Phase 3 intergroup trial. Blood 108, 3295-3301 (2006). (Pubitemid 44794222)
45. Forstpointner R, Unterhalt M, Dreyling M et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantel cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study group (GLSG). Blood 108, 4003-4008 (2006). (Pubitemid 44920177)
46. Gottenberg J, Ravaud P, Bardin T et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab (AIR) registry. Arthritis Rheum. 62, 2625-2632 (2010).
47. Isaacs A, Lindenmann J. Virus interference I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci. 147, 258-267 (1957).
48. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (2004). (Pubitemid 39576902)
49. Krause CD, Pestka S. Evolution of the class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol. Ther. 106, 299-346 (2005). (Pubitemid 40726292)
50. Platanias LC. Mechanisms of type-I-and type-II-interferon mediated signalling. Nat. Rev. Immunol. 5, 375-386 (2005).
51. De Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282, 20053-20057 (2007). (Pubitemid 47099976)
52. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047-20051 (2007). (Pubitemid 47099975)
53. Tough DF, Sun S, Zhang X, Sprent J. Stimulation of naive and memory T cells by cytokines. Immunol. Rev. 170, 39-47 (1999). (Pubitemid 29490743)
54. Ortaldo JR, Mason A, Rehberg E et al. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. J. Biol. Chem. 258, 15011-15015 (1983). (Pubitemid 14175753)
55. Cantell K, Hirvonen S, Kauppinen HL, Myllyla G. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol. 78(Part A), 29-38 (1981).
56. Mellstedt H, Bjorkholm M, Johansson B, Ahre A, Holm G, Strander H. Interferon therapy in myelomatosis. Lancet 313, 245-247 (1979). (Pubitemid 9125147)
57. Kujawski LA, Talpaz M. The role of interferon-A in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev. 18(5-6), 459-471 (2007). (Pubitemid 47302836)
58. Kiladjian JJ, Cassinat B, Turlure P et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon a-2a. Blood 108, 2037-2040 (2006). (Pubitemid 44395018)
59. Kiladjian JJ, Chomienne C, Fenaux P. Interferon-A therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia 22(11), 1990-1998 (2008).
60. Kiladjian JJ, Cassinat B, Chevret S et al. Pegylated interferon-A-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112, 3065-3072 (2008).
61. Larsen TS, Bjerrum OW, Pallisgaard N et al. Sustained major molecular response on interferon a-2b in two patients with polycythemia vera. Ann. Hematol. 87, 847-850 (2008).
62. Larsen TS, Moslash;ller MB, de Stricker K et al. Minimal residual disease and normalization of the bone marrow after long-term treatment with a-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete haematological remission. Hematology 14(6), 331-334 (2009).
63. Hasselbalch HC. Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leuk. Res. 33(1), 11-18 (2009).
64. Silver RT, Vandris K. Recombinant interferon a (rIFN a-2b) may retard progression of early myelofibrosis. Leukemia 23, 1366-1369 (2009).
65. Ianotto JC, Kiladjian JJ, Demory JL et al. PEG-IFN-A-2a therapy in patients with myelofibrosis: A study of the French Groupe dEtudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myé loprolifératifs (FIM). Br. J. Haematol. 146, 223-225 (2009).
66. Quintas-Cardama A, Kantarjian HM, Manshouri T et al. Pegylated interferon-A-2a therapy yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol. 27, 5418-5424 (2009).
67. Bracada S, Eggermont AMM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur. J. Cancer 46, 284-297 (2010).
68. Murphy PT, McPherson S, Langabeer SE. Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-a. Ann. Hematol. 90(2), 233-234 (2011).
69. Hasselbalch HC. Interferon a2 in the treatment of hematological malignancies. status and perspectives. Curr. Drug Targets 12(3), 387-391 (2011).
70. Hasselbalch HC, Larsen TS, Riley CH, Jensen MK, Kiladjian JJ. Interferon a in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. status and perspectives. Curr. Drug Targets 12, 392-419 (2011).
71. Hasselbalch HC, Kiladjian JJ, Silver RT. Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. J. Clin. Oncol. 29, e564-e565 (2011).
72. Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117(18), 706-715 (2011).
73. Silver RT, Vandris K, Goldman JJ. Recombinant interferon a may retard progression of early primary myelofibrosis: A preliminary report. Blood 117(24), 6669-6672 (2011).
74. Preudhomme C, Guilhot J, Nicolini FE et al. SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N. Engl. J. Med. 363(26), 2511-2521 (2010).
75. Simonsson B, Hjorth-Hansen H, Bjerrum OW, Porkka K. Interferon a for treatment of chronic myeloid leukemia. Curr. Drug Targets 12(3), 420-428 (2011).
76. Bjerrum OW. Interferon-A treatment in systemic mastocytosis. Curr. Drug Targets 12(3), 433-436 (2011).
77. Bjerrum OW. Interferon treatment in patients with hypereosinophilia. Curr. Drug Targets 12(3), 429-432 (2011).
78. Berneman ZN, Anguille S, Van Marck V, Schroyens WA, Van Tendeloo VF. Induction of complete remission of acute myeloid leukaemia by pegylated interferon-A-2a in a patient with transformed primary myelofibrosis. Br. J. Haematol. 149(1), 152-155 (2010).
79. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL. Interferon-A in acute myeloid leukemia: An old drug revisited. Leukemia 5, 739-748 (2011).
80. Kimby E, Jurlander J, Geisler C et al. Nordic Lymphoma Group Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon a-2a: A randomized Phase II study from the Nordic Lymphoma Group. Leuk. Lymphoma 49(1), 102-112 (2008). (Pubitemid 351146889)
81. McLaughlin P, Sacchi S. Interferon: does it still have a role in the 21st Century? Leuk. Lymphoma 50(10), 1562-1563 (2009).
82. Baldo P, Rupolo M, Compagnoni A et al. Interferon-A for maintenance of follicular lymphoma. Cochrane Database Syst. Rev. 1, CD004629 (2010).
83. Khoo TL, Vangsted AJ, Joshua D, Gibson J. Interferon-A in the treatment of multiple myeloma. Curr. Drug Targets 12(3), 437-446 (2011).
84. Carlo Stella C, Cazzola M. Interferons as biologic modulators of hematopoietic cell proliferation and differentiation. Haematologica 73(3), 225-237 (1988).
85. Gugliotta L, Bagnara GP, Catani L, Gaggiol L, Guarni A, Zauli G. In vivo and in vitro inhibitory effect of interferon on megakaryocyte colony growth in essential thrombocythemia. Br. J. Haematol. 71, 177-181 (1989). (Pubitemid 19061664)
86. Chott A, Gisslinger H, Thiele J et al. Interferon-A-induced morphological changes of megakaryocytes: A histomorphometrical study on bone marrow biopsies in chronic myeloproliferative disorders with excessive thrombocytosis. Br. J. Haematol. 74, 10-16 (1990). (Pubitemid 20043566)
87. Wadenvik H, Kutti J, Ridelli B et al. The effect of a-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 77, 2103-2108 (1991).
88. Muller CA, Walz J, Zinser R, Buhring HJ, Steinke B, Schmidt H. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN-A treatment. Ann. Hematol. 63, 259-263 (1991).
89. Borden EC, Wadler S. Interferons as biochemical modulators. J. Clin. Oncol. 14(10), 2627-2630 (1996). (Pubitemid 26329645)
90. Grander D, Sangfelt O, Erickson S. How does interferon exert its cell growth inhibitory effect? Eur. J. Hematol. 59, 129-135 (1997). (Pubitemid 27392087)
91. Wang O, Miyakawa Y, Fox N et al. Interferon-A directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1. Blood 96, 2093-2107 (2000).
92. Biron CA. Interferons a and b as immune regulators - a new look. Immunity 14(6), 661-664 (2001). (Pubitemid 32592413)
93. Brassard DL, Grace MJ, Bordens RW. Interferon-A as an immunotherapeutic protein. J. Leucocyte Biol. 71, 565-581 (2002).
94. Borden EC. Review: Milstein Award lecture: interferons and cancer: where from here? J. Interferon Cytokine Res. 25(9), 511-527 (2005). (Pubitemid 41395839)
95. Borden EC, Sen GC, Uze G et al. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6(12), 975-990 (2007). (Pubitemid 350201788)
96. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-a: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43(3), 204-209 (2010).
97. Riley CH, Jensen MK, Brimnes MK et al. Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with interferon-a. Blood 118(8), 2170-2173 (2011).
98. Gamero AM, Young HA, Wiltrout RH. Inactivation of Stat3 in tumor cells: Releasing a brake on immune responses against cancer? Cancer Cell 5, 111-112 (2004). (Pubitemid 38283795)
99. Wang T, Niu G, Kortylewski M et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10, 48-54 (2004). (Pubitemid 38524698)
100. Lesinski GB, Anghelina M, Zimmerer J et al. The antitumor effects of IFN-A are abrogated in A STAT1-deficient mouse. J. Clin. Invest. 112, 170-180 (2003). (Pubitemid 38056353)
101. Yu H, Jove R. The STATs of cancer. New molecular targets come of age. Nat. Rev. 4, 97-105 (2004). (Pubitemid 38198738)
102. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19, 2468-2473 (2000). (Pubitemid 30339202)
103. Burdelya L, Kujawski M, Niu G et al. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide mediated antitumor effects. J. Immunol. 174, 3925-3931 (2005). (Pubitemid 40395966)
104. Yang J, Chatterjee-Kishore M, Staugaitis SM et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res. 65, 939-947 (2005). (Pubitemid 40216455)
105. Skov V, Larsen TS, Thomassen M et al. Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis. Eur. J. Haematol. 87(1), 54-60 (2011).
106. Peschel C, Aulitzky WE, Huber C. Influence of interferon-A on cytokine expression by bone marrow microenvironment - impact on treatment of myeloproliferative disorders. Leuk. Lymph. 22(Suppl. 1), 129-134 (1996). (Pubitemid 26388542)
107. Sacchi S, Leono P, Liberati M et al. A prospective comparison between treatment with phlebotomy alone and interferon-A in patients with polycythemia vera. Ann. Hematol. 68, 247-250 (1994). (Pubitemid 24191896)
108. Brand CM, Leadhester L, Budiman R, Lechner K, Gisslinger H. Succesful re-treatment of an anti-interferon resistant polycythemia vera patient with lymphoblastoid interferon-aN1 and in vitro studies on the specificity of the antibodies. Br. J. Haematol. 86, 216-218 (1994). (Pubitemid 24194412)
109. Merup M, Tornebohm-Roche E, Engman K, Paul C. Human leucocyte interferon-A therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-a2a. Eur. J. Cancer 30A, 1729-1730 (1994). (Pubitemid 24355498)
110. Tornebohm-Roche E, Merup M, Lockner D, Paul C. a-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis. Am. J. Hematol. 48, 163-167 (1994).
111. Stasi R, Brunetti M, Bussa S et al. Efficacy and safety of human leucocyte interferon-A treatment in patients younger than 60 years of age with polycythemia vera. J. Intern. Med. 242, 143-147 (1997). (Pubitemid 27351612)
112. Stasi R, Venditti A, Del Poeta G et al. Role of human leucocyte interferon (a) in the treatment of patients with polycythemia vera. Am. J. Med. Sci. 315, 237-241 (1998). (Pubitemid 28207656)
113. Merup M, Aberg W, Lowenberg E et al. Symptoms, symptom distress and health related quality of life in patients with polycythemia vera or essential thrombocythemia during treatment with interferon-a. Acta Oncol. 41, 50-55 (2002). (Pubitemid 34293359)
114. Yanai Y, Sanou O. Analysis of the antiviral activities of natural IFN-A preparations and their subtype compositions. J. Interferon Cytokine Res. 21, 835-841 (2001). (Pubitemid 33078522)
115. Hibbert L, Foster GR. Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J. Interferon Cytokine Res. 19, 309-318 (1999). (Pubitemid 29210678)
116. Ortaldo JR, Herberman RB. A species of human a interferon that lacks the ability to boost human natural killer activity. Proc. Natl Acad. Sci. USA 81, 4926-4929 (1984). (Pubitemid 14066227)
117. Greiner JW, Fischer PB. Differential effects of recombinant human leucocyte interferons on cell surface antigen expression. Cancer Res. 46, 4984-4990 (1986). (Pubitemid 16008251)
118. Hilkens CMU, Schhlaak JF. Differential responses to IFN-A subtypes in human T cells and dendritic cells. J. Immunol. 171, 5255-5263 (2003). (Pubitemid 37432810)
119. Kawade Y, Watanabe Y. Neutralization of interferon by antibody: Appraisals of methods of determining and expressing the neutralizing titre. J. Interferon Res. 4, 571-584 (1984). (Pubitemid 14023313)
120. Steis RG, Smith JW, Urba WJ et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med. 318, 1409 (1988).
121. Catani L, Gugliotta L, Zauli G et al. In vitro inhibition of interferon a-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythemia. Hematologica 77, 318-321 (1989).
122. von Bussow P, Jakschies D, Freund M et al. Treatment of antirecombinant interferon-A 2 antibody positive patients with natural interferon-a. Br. J. Haematol. 78, 210-216 (1991).
123. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralising antibodies to interferon-a: Relative frequency in patients treated with different interferon preparations. J. Infect. Dis. 163, 882-885 (1991).
124. Singal AK, Jampana SC, Anand BS. Peginterferon a-2a is superior to peginterferon a-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig. Dis. Sci. 56(8), 2221-2226 (2011).
125. Linkesch W, Gisslinger H, Ludwig H, Flener R, Sinzinger H. Therapy with interferon (recombinant IFN-A-2C) in myeloproliferative diseases with severe thrombocytosis. Acta Med. Austriaca 12, 123-127 (1985). (Pubitemid 16128362)
126. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-A in the treatment of essential thrombocythemia. Leuk. Lymphoma 22(Suppl. 1), 135-142 (1996).
127. Barbui T, Barosi G, Birgegard G et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J. Clin. Oncol. 29(6), 761-770 (2011).
128. Middelhoff G, Boll I. A long-term clinical trial of interferon a therapy in essential thrombocythemia. Ann. Hematol. 64, 207-209 (1992).
129. Kasparau H, Bernhard M, Krieger O, Lutz D. Remission may continue after termination of rIFN a-2b treatment for essential thrombocythemia. Eur. J. Hematol. 48, 33-36 (1992).
130. Sacchi S, Tabilio A, Leoni P et al. Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term aIFN treatment. Ann. Hematol. 66, 245-246 (1993). (Pubitemid 23179047)
131. Giles F. Maintenance therapy in myeloproliferative disorders: The current options. Br. J. Haematol. 79(Suppl. 1), 92-95 (1991).
132. Lopes E, Ribeiro MM, Silva MJ, Gandra M, Principe F, Granato C. Essential thrombocythemia: clinical features, therapy and follow up of 12 cases. Leukemia 6(Suppl. 3), 138S-140S (1992).
133. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Interferon in essential thrombocythemia. Br. J. Haematol. 79(Suppl. 1), 42-47 (1991).
134. Alvarado Y, Cortes I, Verstovsek S et al. Pilot study of pegylated interferon a 2b in patients with essential thrombocythemia. Cancer Chemother. Pharmacol. 51, 81-86 (2003). (Pubitemid 36057027)
135. Langer C, Lengfelder E, Thiele J et al. Pegylated interferon for the treatment of high risk essential thrombocythemia: Results of a Phase II study. Haematologica 90, 1333-1338 (2005). (Pubitemid 41503648)
136. Gugliotta L, Bulgarelli S, Vianelli N et al. PEG intron treatment in 90 patients with essential thrombocythemia (ET). Final report of a Phase II study. Blood (ASH Annual Meeting Abstracts) 106, abstract 2600 (2005).
137. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin. Thromb. Hemostas. 32, 409-414 (2006).
138. Samuelsson J, Hasselbalch H, Bruserod O et al. A Phase II trial of pegylated interferon a-2b therapy for polycythemia vera and essential thrombocythemia. Feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106, 2397-2405 (2006). (Pubitemid 43787664)
139. Jabbour E, Kantarjian H, Cortes J et al. PEG-IFN-A-2b therapy in BCR-ABL-negative myeloproliferative disorders. Final results of a Phase 2 study. Cancer 110, 2012-2016 (2007).
140. Berte R, Vallisa D, Ferrai B, Civardi G, Sbolli G, Cavanna L. Low dose interferon a treatment in essential thrombocythemia. Eur. J. Haematol. 56, 104-105 (1996). (Pubitemid 26074516)
141. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419-429 (2001). (Pubitemid 32783703)
142. Bukowski RM, Tandler C, Cutler D, Rose E, Laughlin MM, Statkevich P. Treating cancer with PEG intron: pharmokinetic profile and dosing guidelines for an improved interferon-A- 2b formulation. Cancer 95, 389-396 (2002). (Pubitemid 34787605)
143. Gugliotta L, Bulgarelli S, Asioli S et al. Bone marrow evaluation according to the PVSG and WHO criteria in 90 essential thrombocythemia (ET) patients treated with PEG interferon a-2b. Preliminary results. Blood 106, 316 (2005) (Abstract 4962).
144. Silver RT. Recombinant interferon-A for the treatment of polycythemia vera. Lancet 2, 403 (1988).
145. Silver RT. A new treatment for polycythemia vera: Recombinant interferon a. Blood 76, 664-665 (1990).
146. Sacchi S. The role of a-interferon in essential thrombocythemia, polycythemia vera, and myelofibrosis with myeloid metaplasia. Leuk. Lymphoma 19, 13-20 (1995).
147. Lengfelder E, Berger U, Hehlmann R. Interferon-A in the treatment of polycythemia vera. Ann. Hematol. 79, 103-109 (2000).
148. Foa P, Massaro P, Ribera S et al. Role of interferon a-2a in the treatment of polycythemia vera. Am. J. Hematol. 48, 55-57 (1995).
149. Foa P, Massaro P, Caldiera S et al. Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia vera. Eur. J. Haematol. 60, 273-277 (1998). (Pubitemid 28270750)
150. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-A-2b: feasibility and efficacy. Cancer 83, 1205-1213 (1998). (Pubitemid 28419075)
151. Silver RT. Long-term effects of the treatment of polycythemia vera with recombinant interferon-a. Cancer 107, 451-458 (2006). (Pubitemid 44107203)
152. Parmeggianni L, Ferrant A, Rodhain J, Michaux JL, Sokal G. a interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. Eur. J. Haematol. 39, 228-232 (1987). (Pubitemid 17133321)
153. Wickramasinghe SN, Stanley P, Gill DS. a-interferon in primary myelofibrosis. Lancet 330, 1524-1525 (1987).
154. Hasselbalch H. Interferon in myelofibrosis. Lancet 1, 355 (1988). (Pubitemid 18057779)
155. Barosi G, Libertato LN, Costa A, Ascari E. Cytoreductive effects of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 58, 271-274 (1989). (Pubitemid 19162782)
156. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-A in the
157. Radin AI, Kim HT, Grant BW et al. Phase II study of a2 interferon in the treatment of the chronic myeloproliferative disorders. Cancer 98, 100-109 (2003).
158. Ludwig H, Linkesch W, Gisslinger H et al. Interferon a corrects thrombocytosis in patients with myeloproliferative disorders. Cancer Immunol. Immunother. 25, 266-273 (1987). (Pubitemid 18043614)
159. Muller W, de Wolf JT, Egger R et al. Long-term treatment with interferon-a2b for severe pruritus in patients with polycythemia vera. Br. J. Haematol. 89, 313-318 (1995).
160. Ariad S, Bezwoda WR. a-interferon for polycythemia vera. Blood 77, 670 (1991).
161. Heis N, Rintelen C, Gisslinger B, Knobl P, Lechner K, Gisslinger H. The effect of interferon a on myeloproliferation and vascular complications in polycythemia vera. Eur. J. Haematol. 62, 27-31 (1999). (Pubitemid 29029914)
162. Cacciola E, Giustolisi R, Guglielmo P, Di Raimondo F, Cacciola E, Calogero RD. Recombinant interferon a in the treatment of polycythemia vera. Blood 77, 2790-2796 (1991).
163. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709-718 (2006). (Pubitemid 43247141)
164. Moschos SJ, Edington HD, Land SR et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon a-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J. Clin. Oncol. 24, 3164-3171 (2006). (Pubitemid 46638955)
165. Sacchi S, Kantarjian H, OBrien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J. Clin. Oncol. 13, 2401-2407 (1995).
166. Steegmann JL, Requena MJ, Martin- Regueira P et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-a. Am. J. Hematol. 72, 170-1706 (2003).
167. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost. 32(4 Part 2), 417-421 (2006).
168. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J. Clin. Oncol. 29, 3907-3913 (2011).
169. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br. J. Haematol. 129, 293-306 (2005). (Pubitemid 40646888)
170. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/ polycythemia vera and pregnancy: The need for an observational study in Europe. Semin. Thromb. Hemost. 32(4 Pt 2), 422-429 (2006).
171. Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 22, 235-245 (2008).
172. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica 90, 1477-1483 (2005). (Pubitemid 41658760)
173. Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. The management and outcome of four pregnancies in women with idiopathic myelofibrosis Br. J. Haematol. 142, 480-482 (2008). (Pubitemid 351962173)
174. Passamonti F, Randi ML, Rumi E et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 617F mutation. Blood 110, 485-489 (2007). (Pubitemid 47105385)
175. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis. Haematologica 85, 1126-1134 (2000).
176. Thiele J, Kvasnicka HM, Zankovich R, Diehl V. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann. Hematol. 80, 160-165 (2001). (Pubitemid 32266156)
177. Thiele J, Kvasnicka HM. Prefibrotic chronic idiopathic myelofibrosis - a diagnostic enigma? Acta Hematol. 111, 155-1559 (2004).
178. Thiele J, Kvasnicka HM. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders. Leuk. Lymphoma 47, 381-396 (2006). (Pubitemid 43102085)
179. Wilkins BS, Erber WN, Bareford D et al. Bone marrow pathology in essential thrombocythemia: inter-observer reliablity and utility for identifying disease subtypes. Blood 111, 60-70 (2008).
180. Thiele J, Kvasnicka HM, Mllauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification. Blood 117(21), 5710-5718 (2011).
181. Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110, 840-846 (2007). (Pubitemid 47267419)
182. Vannucchi AM, Antonioli E, Guglielmelli P et al. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia 21, 1952-1959 (2007). (Pubitemid 47299969)
183. Larsen TS, Pallisgaard N, Moller MB, Hasselbalch HC. The JAK2 V617F allelle burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype. Eur. J. Haematol. 79, 508-515 (2007). (Pubitemid 350126669)
184. Barosi G, Bergamaschi G, Marchetti M et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110, 4030-4036 (2007). (Pubitemid 350248459)
185. Kittur J, Knudson RA, Lasho TL et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109, 2279-2284 (2007). (Pubitemid 46801558)
186. Hsiao HH, Yang MY, Liu YC et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp. Hematol. 35, 1704-1707 (2007).
187. Carobbio A, Finazzi G, Guerini V et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109, 2310-2313 (2007). (Pubitemid 46425868)
188. Tefferi A, Strand JJ, Lasho TL et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21, 2074-2075 (2007). (Pubitemid 47299994)
189. Steimle C, Lehmann U, Temerinac S et al. Biomarker analysis in polycythemia vera under interferon-A treatment: clonality, EEC, PRV-1, and JAK2 V617F. Ann. Hematol. 86(4), 239-244 (2007). (Pubitemid 46351398)
190. Ishii T, Xu M, Zhao Y et al. Recurrence of clonal hematopoiesis after discontinuing pegylated recombinant interferon-A 2a in a patient with polycythemia vera. Hematologica 21, 373-374 (2007). (Pubitemid 46158140)
191. Kiladjian JJ, Massé A, Cassinat B et al. French Intergroup of Myeloproliferative Neoplasms (FIM). Clonal analysis of erythroid progenitors suggests that pegylated interferon a-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells. Leukemia 24(8), 1519-1523 (2010).
192. Buxhofer-Ausch V, Gisslinger H, Berg T, Gisslinger B, Kralovics R. Acquired resistance to interferon a therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis. Eur. J. Haematol. 2(2), 161-163 (2009).
193. Sumi M, Tauchi T, Takaku T, Ohyashiki JH, Ohyashiki K. Successful treatment with interferon-A in a case of acute myeloid leukemia with del (20q) following polycythemia vera. Rinsho. Ketsueki. 46(11), 1208-1212 (2005).
194. Essers MA, Offner S, Blanco-Bose WE et al. IFNa activates dormant haematopoietic stem cells in vivo. Nature 458(7240), 904-908 (2009).
195. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med. 15(6), 696-700 (2009).
196. Trumpp A, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. Nat. Rev. Immunol. 10(3), 201-209 (2010).
197. Spivak JL, Hasselbalch HC. Hydroxycarbamide: A users guide for chronic myeloproliferative disorders. Expert Rev. Anticancer Ther. 11(3), 403-414 (2011).
198. Giles FJ, Singer CR, Gray AG et al. Alpha-interferon therapy for essential thrombocythaemia. Lancet 2, 70-72 (1988).
199. Bellucci S, Harousseau JL, Brice P, Tobelem G. Treatment of essential thrombocythaemia by alpha 2a interferon. Lancet 2, 960-961 (1988).
200. Lazzarino M, Vitale A, Morra E et al. Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosis. Br. J. Haematol. 72, 173-177 (1989). (Pubitemid 19151137)
201. Giralt M, Rubio D, Cortes MT et al. Alpha interferon in the management of essential thrombocythaemia. Eur. J. Cancer 27(Suppl. 4), S72-S74 (1991).
202. Sacchi S, Tabilio A, Leoni P et al. Interferon alpha-2b in the long-term treatment of essential thrombocythemia. Ann. Hematol. 63, 206-209 (1991).
203. Turri D, Mitra ME, Di Trapani R, Lipari MG, Perricone R, Cajozzo A. Alpha-interferon in polycythemia vera and essential thrombocythemia. Haematologica 76, 75-77 (1991).
204. Seewann HL, Zikulnig R, Gallhofer G, Schmid C. Treatment of thrombocytosis in chronic myeloproliferative disorders with interferon alfa-2b. Eur. J. Cancer 27(Suppl. 4), S58-S62; discussion S58-S62 (1991).
205. Kasparu H, Bernhard M, Krieger O, Lutz D. Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia. Eur. J. Hematol. 48, 33-36 (1992).
206. Rametta V, Ferrara F, Marottoli V, Matera C, Mettivier V, Cimino R. Recombinant interferon alpha-2b as treatment of essential thrombocythaemia. Acta Haematol. 91, 126-129 (1994). (Pubitemid 24279890)
207. Sacchi S, Gugliotta L, Papineschi F et al. Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET. Leukemia 12, 289-294 (1998). (Pubitemid 28138211)
208. Saba R, Jabbour E, Giles F et al. Interferon alpha therapy for patients with essential thrombocythemia: final results of a Phase II study initiated in 1986. Cancer 103, 2551-2557 (2005). (Pubitemid 40800534)
209. Cimino R, Rametta V, Matera C, Mele G, Mettivier V, Ferra F. Recombinant interferon alpha-2b in the treatment of polycythemia vera. Am. J. Hematol. 44, 155-157 (1993). (Pubitemid 23295695)
210. Finelli C, Gugliotta L, Gamberi B, Vianelli N, Visani G, Tura S. Relief of intractable pruritus in polycythemia vera with recombinant interferon alpha. Am. J. Hemol. 43, 316-318 (1993). (Pubitemid 23205217)
211. Papineschi F, Bucallossi A, Capochiani E et al. Recombinant alpha2a interferon and polycythemia vera: clinical results and biological evaluation by means of Fourier-transform infrared microspectroscopy. Eur. J. Haematol. 53, 213-217 (1994). (Pubitemid 24347965)
212. Taylor PC, Dolan G, Ng JP, Paul B, Collin R, Reilly JT. Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: A study of 17 patients and an analysis of published data. Br. J. Haematol. 92(1), 55-59 (1996). (Pubitemid 26020697)
213. Tefferi A, Elliot MA, Yoon SY et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 97(6), 1896 (2001).(Pubitemid 32217264)